The Smart Money Is Hoarding Shares of These 10 Healthcare Stocks: Part 1

#3 Seattle Genetics, Inc. (NASDAQ:SGEN)

Number of Hedge Fund Holders (as of September 30): 21
Total Value of Hedge Fund Holdings (as of September 30): $2.09 billion
Hedge Fund Holdings as Percent of Float (as of September 30): 43.30%

Although the analysts at Goldman think Adcetris’ label expansion is already priced into the stock and Seattle Genetics, Inc. (NASDAQ:SGEN)’s pipeline potential is uncertain, Goldman is going against the grain. Seven analysts have ‘Buy’ ratings, five have ‘Hold’ ratings, and only two analysts have ‘Sell’ ratings on the biotech company. Moreover, the hedge fund crowd is becoming more bullish, as the number of hedge funds long the stock increased by 5 quarter-over-quarter to 21. The total amount of elite fund holdings in Seattle Genetics also increased to $2.09 billion from $1.62 billion a quarter ago. Healthcare-focused investors Julian and Felix Bakers’ are betting big on Seattle Genetics. Their fund, Baker Bros. Advisors, disclosed ownership of 36.03 million shares of the company in its latest 13F filing.

#2 Brookdale Senior Living, Inc. (NYSE:BKD)

Number of Hedge Fund Holders (as of September 30): 66
Total Value of Hedge Fund Holdings (as of September 30): $2.17 billion
Hedge Fund Holdings as Percent of Float (as of September 30): 51.20%

For its third quarter, Brookdale Senior Living, Inc. (NYSE:BKD) reported a FFO/share of $0.59, exceeding estimates by $0.01 per share. Revenue grew 14.8% year-over-year to $1.24 billion, in-line with expectations. Given the company’s forward PE of 7.16, many hedge funds are going the opposite way of the market and are accumulating shares. Larry Robbins’ Glenview Capital owned 17.64 million shares of Brookdale Senior Living at the end of September.